EMA/415023/2010

# European Medicines Agency decision

P/105/2010

of 25 June 2010

on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor) (EMEA-000019-PIP02-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/105/2010

of 25 June 2010

on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor) (EMEA-000019-PIP02-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/124/2008 issued on 5 December 2008,

Having regard to the application submitted by Novartis Europharm Ltd on 1 April 2010 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver and proposing a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 June 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision on the granting of a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for everolimus (Afinitor), tablet, dispersible tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

A deferral for everolimus (Afinitor), tablet, dispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

***Article 3***

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, RH12 5AB Horsham, West Sussex, United Kingdom.

Done at London, 25 June 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/360493/2010

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan and granting of a deferral

EMEA-000019-PIP02-07-M01

## Scope of the application

**Active substance(s):**

Everolimus

**Invented name:**

Afinitor

**Condition(s):**

Subependymal giant cell astrocytoma

Angiomyolipoma

**Pharmaceutical form(s):**

Tablet

Dispersible tablet

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Novartis Europharm Ltd

**Information about the authorised medicinal product:**

See Annex II

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Ltd submitted to the European Medicines Agency on 1 April 2010 an application for modification of the

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/124/2008 issued on 5 December 2008.

The application for modification proposed changes to the agreed paediatric investigation plan and proposed a deferral.

The procedure started on 15 April 2010.

## Scope of the modification

Modification of some measures and timelines and granting of a deferral.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion,
   - to grant a deferral, the details of which are set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexe) and appendix.

London, 11 June 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

# Annex I

# The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

# 1. Condition(s)

Subependymal giant cell astrocytoma

Angiomyolipoma

# 2. Waiver

## *2.1. Condition*

Angiomyolipoma

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
- for tablet for oral use and dispersible tablet for oral use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

# 3. Paediatric Investigation Plan

## *3.1. Condition to be investigated*

Subependymal giant cell astrocytoma

### 3.1.1. Indication targeted by the PIP

Treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC)

### 3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years

### 3.1.3. Pharmaceutical form(s)

Tablet for oral use

Dispersible tablet for oral use, including strengths of 2 mg, 2.5 mg and 3 mg

### 3.1.4. Studies

| Area | Number of studies | Description |
|---|---|---|
| Quality | - | Not applicable |
| Non-clinical | - | Not applicable |
| Clinical | 3 | 1. Relative bioavailability study between intact 1 mg tablet and 1 mg tablet dispersed in water in adults<br>2. Bioequivalence study between intact 1 mg tablet and 5 mg dispersible tablet in adults |

| | | |
|---|---|---|
| | | 3. Randomized, double-blind, placebo-controlled, parallel-group, dose-titration, comparative, multi-centre study to evaluate pharmacokinetics, safety, tolerability and activity of everolimus in children from birth to less than 18 years of age |

# 4. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Measures to address long term follow-up of potential safety issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By September 2012 |
| Deferral for initiation of some or all studies contained in the paediatric investigation plan: | Yes |

# Annex II

# Information about the authorised medicinal product

| EU Number | (Invented) name | Strength | Pharmaceutical Form | Route of Administration | Packaging | Package size |
|---|---|---|---|---|---|---|
| EU/1/09/538/001 | Afinitor | 5 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 30 tablets |
| EU/1/09/538/002 | Afinitor | 5 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 60 tablets |
| EU/1/09/538/003 | Afinitor | 5 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 90 tablets |
| EU/1/09/538/004 | Afinitor | 10 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 30 tablets |
| EU/1/09/538/005 | Afinitor | 10 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 60 tablets |
| EU/1/09/538/006 | Afinitor | 10 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 90 tablets |
| EU/1/09/538/007 | Afinitor | 5 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 10 tablets |
| EU/1/09/538/008 | Afinitor | 10 mg | Tablet | Oral use | blister (alu/PA/alu/PVC) | 10 tablets |